21 May 2021 (Friday) - Chromic Leukaemias

The nice people at the American Society of Hematology sent me an update on the latest developments in chronic leukaemias. Rather clinical, a little over my head in places… but valuable background reading.

Here are the highlights in chronic leukemias:

Acalabrutinib Induces Durable Remission in Patients With Treatment Naïve Chronic Lymphocytic Leukemia
Treatment with the next-generation covalent BTK inhibitor was safe and led to durable, long-term remission in a small group of patients with previously untreated CLL, according to a study published in Blood.
FDA Grants Breakthrough Therapy Designation to Asciminib for CML
The FDA’s decision is based on data from the phase III ASCEMBL trial evaluating asciminib for the treatment of patients with Ph+ CML in chronic phase, including those who harbor the T315I mutation.
Trilaciclib Approved for Chemotherapy-Induced Myelosuppression
The FDA has approved trilaciclib to reduce the frequency of myelosuppression in adult patients receiving certain types of chemotherapy for extensive-stage small cell lung cancer.


No comments:

Post a Comment